Vaughn joined Microbix’ Board of Directors in 2007, and he was appointed President and CEO in late 2012. He has refocussed the Company’s strategy, including a commitment to deliver sustained profitability. In 2013, the Company recorded its first profit in a decade, which continued in 2014. Vaughn has held C-level positions in the pharmaceutical industry, including at Teva and Bayer; and he has a Masters of Business Administration degree from the University of Windsor and he is a Fellow Chartered Professional Accountant.
Jim joined Microbix as Chief Financial Officer in November 2016. He brings significant financial and operations management experience in manufacturing and life science businesses. He was most recently the CFO at SMTC Corporation, a publicly traded global electronics manufacturing company. Prior to that he was CFO at Kapsch TrafficCom, a leader in highway tolling technology and Vice-President, Finance at MDS SCIEX, a global leader in life science and analytical technologies. Jim has a Bachelor of Commerce from the University of Toronto and is a CPA, CMA.
Since joining Microbix in 2003, he has lead the growth of the core business by more than 400% and has held various positions including General Manager and President. He graduated in 1985 from the University of Ottawa with a Bachelor of Applied Science in Chemical Engineering and has over 30 years experience in the biotech and pharmaceutical industries.
Kevin is responsible for Microbix’ Kinlytic brand biopharmaceutical product used for treatment of pulmonary embolism and biomedical catheter management. He has a BSc and over 30 years of experience in the biotech and healthcare industries. He is credited with development of the Company’s leading antigen products and establishment of GMP operations in Canada, China and Chile. In his tenure at Microbix Mr. Cassidy has held numerous roles including heading up company diagnostic product operations.
Mark is responsible for Microbix’ scientific programs, he is a specialist in cell biology, immunovirology, and cytometry. Originator of Microbix’ LumiSort technology, he is inventor on numerous patents and patent applications related to the technology, filed in countries worldwide. He works actively on the program to deliver LumiSort to the artificial insemination industry, while overseeing scientific and technological programs and initiatives related to Microbix’ Diagnostic Products business. He earned his doctorate in Immunology at the University of Toronto in 1997, and has coauthored over 30 peer-reviewed publications.
Kathryn has more than 25 years of experience in the biotech industry. She was appointed to the role Vice-President, Diagnostic Products in May 2014, and now oversees all manufacturing, testing and quality activities for Microbix’ Diagnostic Products division. She has been with Microbix for over 15 years in a variety of roles including leadership positions in Research and Development and as Director, Operations prior to assuming this position. She obtained her B.Sc. in Life Sciences from Queen’s University at Kingston.
Amer is responsible for leading and advancing the company’s R&D initiatives within the diagnostic reagent division. Since joining Microbix in 2007, he was focused on new product development, improving process efficiencies and has acted as a scientific liaison with Microbix’ clients. Prior to joining Microbix, he worked on clinical assays for detection of cardiac markers and is responsible for several patents and patent applications. He earned his BSc, MSc and PhD in biological chemistry from the University of Toronto and MBA from the Rotman School of Management (University of Toronto).